Phenotyping and Genotyping of Duffy Antigen (DARC)
November 7, 2023 updated by: University Hospital, Strasbourg, France
Malaria remains the world's leading parasitic endemic.
Almost half of the world's population lives in endemic areas.
Many at-risk people in African countries remain without access to malaria control.
Malaria kills approximately 400,000 people each year, most of whom are children under the age of 5 in Africa.
Since 2005, an increasing number of Plasmodium vivax infections have been observed in Duffy-negative populations in South America and Africa, calling into question the essential role of the PvDBP-DARC interaction.
The objective of the investigators is therefore to study and understand the invasion pathways used by Plasmodium vivax in Duffy-negative subjects.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
30
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Strasbourg, France, 67091
- Service de Laboratoire de Parasitologie et Mycologie Médicale-PTM - CHU de Strasbourg - France
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Sampling Method
Non-Probability Sample
Study Population
- Major subjects with malaria and willing to have their blood samples analyzed for this research
Description
Inclusion Criteria:
- Major subjects
- with malaria and willing to have their blood samples analyzed for this research
Exclusion Criteria:
- Subjects refusing to participate in the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of blood samples tested (phenotype and genotype).
Time Frame: 2 months later
|
2 months later
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Didier MENARD, MD, PhD, Service Laboratoire de Parasitologie et Mycologie Médicale-PTM - CHU de Strasbourg - France
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 11, 2022
Primary Completion (Actual)
July 11, 2023
Study Completion (Actual)
September 11, 2023
Study Registration Dates
First Submitted
August 30, 2022
First Submitted That Met QC Criteria
September 1, 2022
First Posted (Actual)
September 2, 2022
Study Record Updates
Last Update Posted (Estimated)
November 8, 2023
Last Update Submitted That Met QC Criteria
November 7, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 8543 (Other Identifier: CTEP)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.